Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited. METHODS: In this 3-year open-label, multicenter trial, we evaluated 708 patients who had suboptimal glycated hemoglobin levels while taking metformin and sulfonylurea therapy. Patients were randomly assigned to receive biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily (twice if required). Sulfonylurea therapy was replaced by a second type of insulin if hyperglycemia became unacceptable during the first year of the study or subsequently if glycated hemoglobin levels were more than 6.5%. Outcome measures were glycated hemoglobin levels, the proportion of patients with a glycated hemoglobin level of 6.5% or less, the rate of hypoglycemia, and weight gain. RESULTS: Median glycated hemoglobin levels were similar for patients receiving biphasic (7.1%), prandial (6.8%), and basal (6.9%) insulin-based regimens (P=0.28). However, fewer patients had a level of 6.5% or less in the biphasic group (31.9%) than in the prandial group (44.7%, P=0.006) or in the basal group (43.2%, P=0.03), with 67.7%, 73.6%, and 81.6%, respectively, taking a second type of insulin (P=0.002). [corrected] Median rates of hypoglycemia per patient per year were lowest in the basal group (1.7), higher in the biphasic group (3.0), and highest in the prandial group (5.7) (P<0.001 for the overall comparison). The mean weight gain was higher in the prandial group than in either the biphasic group or the basal group. Other adverse event rates were similar in the three groups. CONCLUSIONS: Patients who added a basal or prandial insulin-based regimen to oral therapy had better glycated hemoglobin control than patients who added a biphasic insulin-based regimen. Fewer hypoglycemic episodes and less weight gain occurred in patients adding basal insulin. (Current Controlled Trials number, ISRCTN51125379.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because many persons do not achieve adequate glycemic control with monotherapy or are at risk for early loss of efficacy with metformin or another monotherapy, combining antihyperglycemic agents is often appropriate.1060”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1060]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationOhkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 783
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Self-citationHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Self-citation
Research works printed but not linked: 2
- Horvath K, 2007, Cochrane Database Syst Rev, 2, CD005613
- Siebenhofer A, 2006, Cochrane Database Syst Rev, 2, CD003287
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
“and/or symptomatic, a ‘basal’ insulin alone is typically added [74].”
BackgroundManagement of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Self-citationPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
“7 kg, detemir vs biphasic vs prandial, respectively) (93), and the weight advantage persisted during the 3-year trial (94).”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 467
Hayati Rezvan, P., Lee, K. J., & Simpson, J. A. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0022-1 · Cited by 459
“Results Overall, we identified 103 published articles using MI during the study period (Figure 1) [32-134].”
BackgroundMethodHypoglycemia, Diabetes, and Cardiovascular Events
Desouza, C. V., Bolli, G. B., & Fonseca, V. (2010) · Diabetes Care · doi:10.2337/dc09-2082 · Cited by 443
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.154 · Cited by 286
Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes
Courcoulas, A. P., Patti, M. E., Hu, B., Arterburn, D. E., Simonson, D. C., Gourash, W. F., Jakicic, J. M., Vernon, A. H., Beck, G. J., Schauer, P. R., et al. (2024) · JAMA · doi:10.1001/jama.2024.0318 · Cited by 284
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Hypoglycemia: The neglected complication
Kalra, S., Mukherjee, J. J., Venkataraman, S., Bantwal, G., Shaikh, S., Saboo, B., Das, A. K., & Ramachandran, A. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.117219 · Cited by 255
Rosenstock, J., Jelaska, A., Zeller, C., Kim, G., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA‐REG BASAL trial investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12503 · Cited by 252
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 246
“considered over premixed insulin or bolus only regimens, if lower risk of hypoglycemia and/or weight gain are priorities [Grade B, Level 2 (101)].”
Ritzel, R., Roussel, R., Bolli, G. B., Vinet, L., Brulle‐Wohlhueter, C., Glezer, S., & Yki‐Järvinen, H. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12485 · Cited by 236
“regimen, because it has a lower risk for inducing hypoglycaemia and causes less weight gain compared with premixed insulin or multiple daily injection therapy (basal plus bolus therapy) [3].”
BackgroundKhunti, K., Nikolajsen, A., Thorsted, B. L., Andersen, M., Davies, M. J., & Paul, S. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12626 · Cited by 256
“Initiation of insulin treatment with basal insulin is often a preferred option for primary care physicians for its logistic ease and also for its relatively low risk of hypoglycaemia [15,17,18]; however, there is no fixed standard for intensification of insulin treatment in patients who continue to have poor glycaemic…”
BackgroundSelf-citationDiamant, M., Nauck, M. A., Shaginian, R., Malone, J. K., Cleall, S., Reaney, M., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 228
Rosenstock, J., Fonseca, V. A., Gross, J. L., Ratner, R. E., Ahrén, B., Chow, F. C. C., Yang, F., Miller, D., Johnson, S. L., Stewart, M. W., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0001 · Cited by 211
Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
Saisho, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018381 · Cited by 195
“although the use of prandial insulin results in a higher risk of hypoglycemia and weight gain compared with the use of basal insulin [128].”
BackgroundCoppell, K. J., Kataoka, M., Williams, S. M., Chisholm, A. W., Vorgers, S. M., & Mann, J. I. (2010) · BMJ · doi:10.1136/bmj.c3337 · Cited by 199
“Moreover, the addition of insulin for patients on maximally tolerated sulphonylureas and metformin has the potential for additional weight gain and increased risk of hypoglycaemic episodes.”
BackgroundHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0255-6 · Cited by 188
“a higher risk for non-severe hypoglycemia than treatment with basal insulin alone [4], and intensive insulin treatment for the management of type 2 diabetes further increases the risk for severe hypoglycemia [5].”
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Glycemic Management of Type 2 Diabetes Mellitus
Ismail-Beigi, F. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1013127 · Cited by 177
The Contribution of Glucose Variability to Asymptomatic Hypoglycemia in Persons with Type 2 Diabetes
Monnier, L., Wojtusciszyn, A., Colette, C., & Owens, D. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0049 · Cited by 168
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
Home, P., Riddle, M., Cefalu, W. T., Bailey, C. J., Bretzel, R. G., del Prato, S., Leroith, D., Schernthaner, G., van Gaal, L., & Raz, I. (2014) · Diabetes Care · doi:10.2337/dc13-2743 · Cited by 167
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“Initiation of insulin therapy [Figures 3 and 4] • As initial therapy, unless the patient is passing through an acute medical, surgical or obstetric crisis, or in metabolic decompensation, premixed or basal insulin is typically initiated [Tables 5 and 6].[219,221,232,233] General concept is to first correct the fasting…”
BackgroundDeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1928 · Cited by 159
Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes
Ross, S. A. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.012 · Cited by 163
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
Lipscombe, L., Butalia, S., Dasgupta, K., Eurich, D. T., MacCallum, L., Shah, B. R., Simpson, S., & Senior, P. A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.001 · Cited by 153
“hypoglycemia and/or preventing weight gain are priorities [Grade B, Level 2 (50)].”
BackgroundInsulin Therapy for Type 2 Diabetes Mellitus
Wallia, A., & Molitch, M. E. (2014) · JAMA · doi:10.1001/jama.2014.5951 · Cited by 177
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes
Ross, S. A., Tildesley, H. D., & Ashkenas, J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.621416 · Cited by 152
Intensified glucose lowering in type 2 diabetes: time for a reappraisal
Yudkin, J. S., Richter, B., & Gale, E. A. M. (2010) · Diabetologia · doi:10.1007/s00125-010-1864-z · Cited by 156
“Furthermore, and in stark contrast to lipid-lowering or antihypertensive therapies, intensive glucose-lowering may require several injections each day [45], requires regular fingerprick blood testing and is associated with side effects that include hypoglycaemia and loss of consciousness, and perhaps an increased futu…”
BackgroundPozzilli, P., Norwood, P., Jódar, E., Davies, M. J., Ivanyi, T., Jiang, H., Woodward, D. B., & Milicevic, Z. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12937 · Cited by 137
“deterioration occurs in most patients, requiring further insulin dose uptitration.(5,6) Interest in the addition of GLP-1RAs to basal insulin therapy has recently increased as a result of their complementary effects on gly-”
BackgroundSelf-citationPharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., Ceriello, A., & Esposito, K. (2011) · Diabetes Care · doi:10.2337/dc10-1710 · Cited by 128
Vijan, S. S. (2015) · Annals of Internal Medicine · doi:10.7326/aitc201503030 · Cited by 138
RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 159
Rosenstock, J., Lorber, D. L., Gnudi, L., Howard, C. P., Bilheimer, D. W., Chang, P.-C., Petrucci, R., Boss, A., & Richardson, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60632-0 · Cited by 122
Pīrāgs, V., Lebovitz, H. E., & Fouqueray, P. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01611.x · Cited by 130
“The proportion of controlled T2DM patients decreases as disease duration progresses; therefore increasing combinations of pharmacological therapy are frequently required to achieve and/or maintain this level [8].”
BackgroundHypoglycemia in Patients with Diabetes and Renal Disease
Alsahli, M., & Gerich, J. E. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050948 · Cited by 137
Kirwan, J. P., Courcoulas, A. P., Cummings, D. E., Goldfine, A. B., Kashyap, S. R., Simonson, D. C., Arterburn, D. E., GOURASH, W. F., Vernon, A. H., Jakicic, J. M., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2441 · Cited by 136
Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery
Cummings, D. E., & COHEN, R. V. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70198-0 · Cited by 125
Bergenstal, R. M., Rosenstock, J., Arakaki, R. F., PRINCE, M. J., Qu, Y., Sinha, V. P., Howey, D. C., & Jacober, S. J. (2012) · Diabetes Care · doi:10.2337/dc12-0060 · Cited by 115
Imran, S. A., Agarwal, G., Bajaj, H. S., & Ross, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.030 · Cited by 113
Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
“Although at 1 year the reduction in HbA1c was greatest in patients receiving the prandial insulin, this was not seen at 3 years.(124,125) In a noninterventional observational study, a comparison of basal and pre-”
BackgroundFulcher, G. R., Christiansen, J. S., Bantwal, G., Polaszewska-Muszyńska, M., Mersebach, H., Andersen, T. H., & NISKANEN, L. K. (2014) · Diabetes Care · doi:10.2337/dc13-2908 · Cited by 111
Pontiroli, A. E., Miele, L., & Morabito, A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01433.x · Cited by 116
New forms of insulin and insulin therapies for the treatment of type 2 diabetes
Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 109
The application of simple metrics in the assessment of glycaemic variability
Monnier, L., Colette, C., & Owens, D. R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.008 · Cited by 115
Clinical Evidence for the Earlier Initiation of Insulin Therapy in Type 2 Diabetes
Owens, D. R. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0081 · Cited by 122
“0%, whereas treatment with basal insulin detemir was associated with significantly lower rates of hypoglycemia and less weight gain compared with prandial and premixed insulin regimens.(48) This study supports the principle that basal insulin provides a simple and convenient method of initiating insulin therapy, with…”
Speck, M., Cho, Y. M., Asadi, A., Rubino, F., & Kieffer, T. J. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00422.2010 · Cited by 108
Singh, S., Wright, E. E., Kwan, A. Y. M., Thompson, J. C., Syed, I. A., Korol, E. E., Waser, N. A., Yu, M. B., & Juneja, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12805 · Cited by 101
Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Al Shammari, S., Shrestha, D., Shaikh, K., et al. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_556_17 · Cited by 101
“[144] However, after 3 years, basal or prandial insulin-based regimen had better A1C control than biphasic insulin-based regimen.[145]”
BackgroundType 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk
Gerich (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8216 · Cited by 123
Pramlintide and the treatment of diabetes: a review of the data since its introduction
Younk, L. M., Mikeladze, M., & Davis, S. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.581663 · Cited by 111
“There is also inconsistency in the literature regarding the superiority of PPG versus FPG to reduce hemoglobin A1c (HbA1c) [13,15-16].”
BackgroundOwens, D. R., Luzio, S. D., Sert-Langeron, C., & Riddle, M. C. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01459.x · Cited by 99
“Recognized limitations of the first option include limited flexibility in insulin dose adjustment resulting in the need for relatively strict lifestyle changes, more frequent hypoglycaemia, and greater weight gain [3,4].”
Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B. H., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R. W., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 107
“... or prandial (insulin aspart [B28Asp human insulin]based) insulin regimens provided better glycaemic control when added to oral therapy vs adding to a biphasic (aspart-based) regimen, total insulin dose was highest in the basal group (88 U), prandial insulin use was higher in the basal group (51 vs 28 U in the biph…”
BackgroundGlucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 102
Heise, T., Tack, C. J., Cuddihy, R. M., Davidson, J. A., Gouet, D., Liebl, A., Romero, E., Mersebach, H., Dykiel, P., & Jorde, R. (2011) · Diabetes Care · doi:10.2337/dc10-1905 · Cited by 98
Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
Lebovitz, H. E. (2011) · Diabetes Care · doi:10.2337/dc11-s225 · Cited by 115
“To Target in Type 2 Diabetes (4-T) study, which added insulin therapy to patients inadequately controlled on oral therapies, were able to achieve and maintain HbA1c at ~7% by combining multiple different insulin strategies and progressively increasing the daily doses of insulin administered (11).”
BackgroundInfluentialTratamiento de la diabetes tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Díez‐Espino, J., Formiga, F., Tejedor, J. L., Rodríguez‐Mañas, L., González-Sarmiento, E., Torre, E. L. M., & Sangrós, J. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.10.003 · Cited by 111
Impact of weight gain on outcomes in type 2 diabetes
Ross, S. A., Dzida, G. J., Vora, J. P., Khunti, K., Kaiser, M., & Ligthelm, R. J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.585396 · Cited by 99
Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes
Fouqueray, P., Leverve, X. M., Fontaine, E. M., Baquié, M., & Wollheim, C. B. (2011) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000126 · Cited by 94
Bergenstal, R. M., Johnson, M., Passi, R., Bhargava, A., Young, N., Kruger, D. F., Bashan, E., Bisgaier, S. G., Isaman, D. J. M., & Hodish, I. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30368-x · Cited by 88
“As the authors have demonstrated, due to the small but steady nature of the d-Nav’s dosage increments, more than 6 months are needed to allow HbA1c and insulin requirements to stabilize(26).”
BackgroundResultGlucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
Shyangdan, D., Royle, P., Clar, C., Sharma, P., & Waugh, N. R. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-20 · Cited by 96
“In that situation the comparator would be insulin, and following the 4T study [63], the first choice of insulin would be a once daily basal.”
BackgroundBarriers to Insulin Progression Among Patients With Type 2 Diabetes
Polinski, J. M., Smith, B. F., Curtis, B. H., Seeger, J. D., Choudhry, N. K., Connolly, J. G., & Shrank, W. H. (2012) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721712467696 · Cited by 86
Giugliano, D., Chiodini, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2015) · Endocrine · doi:10.1007/s12020-015-0718-3 · Cited by 89
Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir
Davies, M., Heller, S., Sreenan, S., Sapin, H., Adetunji, O., Tahbaz, A., & Vora, J. (2013) · Diabetes Care · doi:10.2337/dc12-1333 · Cited by 83
Self-citationWeight Beneficial Treatments for Type 2 Diabetes
Meneghini, L. F., Orozco‐Beltrán, D., Khunti, K., Caputo, S., Damçi, T., Liebl, A., & Ross, S. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1074 · Cited by 83
Buse, J. B., Rodbard, H. W., Serrano, C. T., Luo, J., Iványi, T., Bue‐Valleskey, J. M., Hartman, M. L., Carey, M. A., & Chang, A. M. (2015) · Diabetes Care · doi:10.2337/dc15-1531 · Cited by 82
Hypoglycemia, Chronic Kidney Disease, and Diabetes Mellitus
Alsahli, M., & Gerich, J. E. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.07.013 · Cited by 89
“30-300 3-30 (30-300) A2 (moderately increased)”
Zhou, H., Zhu, J., Liu, L., Fan, L., Fish, A. F., Chen, T., & Lou, Q. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.02.049 · Cited by 81
Vijan, S. S. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201911050 · Cited by 78
Inagaki, N., Harashima, S., Maruyama, N., Kawaguchi, Y., Goda, M., & Iijima, H. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0407-4 · Cited by 74
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes
Amod, A. (2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872276 · Cited by 72
Arnolds, S., Kuglin, B., Kapitza, C., & Heise, T. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02470.x · Cited by 69
Type 2 diabetes mellitus—current therapies and the emergence of surgical options
Lebovitz, H. E. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.10 · Cited by 73
“An intensive basal-bolus insulin regimen with insulin sensitizers might be necessary in some patients with T2DM who have not been able to achieve their target glycemic goal with combinations of other agents”
BackgroundRosenstock, J., Shenouda, S. K., Bergenstal, R. M., Buse, J. B., Glass, L. C., Heilmann, C. R., Kwan, A. Y. M., MacConell, L., & Hoogwerf, B. J. (2012) · Diabetes Care · doi:10.2337/dc11-1434 · Cited by 66
BAJAJ, H. S., Venn, K., Ye, C., Patrick, A., Kalra, S., Khandwala, H. M., Aslam, N., Twum-Barima, D., & Aronson, R. (2016) · Diabetes Care · doi:10.2337/dc16-1582 · Cited by 65
2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 84
Insulin – Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy
Donner, T. W., & Sarkar, S. (2015) · Europe PMC (PubMed Central) · Cited by 86
Vaag, A. A., & Lund, S. S. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0022 · Cited by 67
Targeting pancreatic β cells for diabetes treatment
Jain, C., Ansarullah, M., Bilekova, S., & Lickert, H. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00618-5 · Cited by 71
Bloomfield, H. E., Greer, N. L., Newman, D. R., MacDonald, R. H., Carlyle, M. H., FITZGERALD, P. J., Rutks, I. R., & Wilt, T. J. (2012) · Cited by 89
Lee, M. Y., Choi, D. S., Lee, M. K., Lee, H. W., Park, T. S., Kim, D. M., Chung, C. H., Kim, D. K., Kim, I. J., Jang, H. C., et al. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.1.90 · Cited by 64
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised)
(2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872287 · Cited by 69
Edelman, S. V., Bode, B. W., Bailey, T. S., Kipnes, M. S., Brunelle, R. L., Chen, X., & Frías, J. P. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0034 · Cited by 60
Insulin management of type 2 diabetes mellitus.
Petznick, A. M. (2011) · PubMed · doi:10.1016/s0002-838x(11)60220-7 · Cited by 58
Evaluation of a Remote Monitoring System for Diabetes Control
Katalenich, B., Shi, L., Liu, S., Shao, H., McDuffie, R. H., Carpio, G., Thethi, T. K., & Fonseca, V. A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.03.022 · Cited by 56
Gagnon‐Auger, M., du Souich, P., Baillargeon, J., Martin, É., Brassard, P., Ménard, J., & Ardilouze, J. (2010) · Diabetes Care · doi:10.2337/dc10-1126 · Cited by 56
“Recent large studies (24,25) provided no evidence supporting the use of preprandial insulins compared with basal insulins.”
Background
Metadata
- Authors
- Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K.
- Affiliations
- University of Oxford (GB)
- University of Leicester (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-29
- Volume
- 361
- Issue
- 18
- Pages
- 1736-1747
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2057595002
- Cited by
- 667
- References
- 26
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 10 · 2023: 12 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 27 · 2018: 33 · 2017: 45 · 2016: 46 · 2015: 49 · 2014: 68 · 2013: 60 · 2012: 78
- FWCI
- 57.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin therapy, biphasic insulin aspart, insulin detemir, basal insulin, HbA1c, glycemic control, hypoglycemia, weight gain, metformin, sulfonylureas
- MeSH terms
- Administration, Oral, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.